Advanced Filters
noise

Fridley, Minnesota Clinical Trials

A listing of Fridley, Minnesota clinical trials actively recruiting patient volunteers.

Found 494 clinical trials
C Carolyn Bramante, MD

Self-Weighing for Adolescents Seeking Obesity Treatment

99 patients age 12 to <18 years old with obesity (BMI >/=95th percentile), will be randomized to one of three treatment interventions: Usual Care Usual Care plus advice to weigh daily on simple scale Usual Care plus advice to weigh-daily on an EHR-connected scale Survey data collected at baseline, 2, …

12 - 17 years of age All Phase N/A

Tdcs And cogNitive traininG cOmbined for AUD (TANGO)

The overarching goal of this project is to expand the traditional expertise in non-invasive neuromodulation at the University of Minnesota towards developing novel paired-neuromodulation approaches using transcranial direct current stimulation (tDCS) for new treatments for alcohol use disorder (AUD) that support long-term abstinence. This study will allow the investigators to …

18 - 65 years of age All Phase N/A
R Rita Mehta, MD

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by …

18 - 70 years of age All Phase 3
J Jeffrey R Wozniak, Ph.D.

CIFASD 5 tDCS and Cognitive Training

This is a randomized placebo-controlled trial of cognitive training with transcranial direct current stimulation (tDCS) for children and adolescents (ages 8 - 17 years) with prenatal alcohol exposure (PAE).

8 - 17 years of age All Phase N/A

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

This study will evaluate the efficacy of TNX-103 (levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).

18 - 85 years of age All Phase 3
L Lisa Burke, RN

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP).

- 55 years of age All Phase 2

BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease

This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD

18 - 35 years of age All Phase 1/2
M Matthew Johnson, PhD

Algorithms for Programming DBS Systems for ET

Deep brain stimulation (DBS) targeting the Vim thalamus (ventralis intermedius nucleus) is an FDA-approved neuromodulation therapy for treating postural and action tremor in individuals with essential tremor (ET). The success of this treatment, however, is highly dependent on the ability of clinicians to identify therapeutic stimulation settings through a laborious …

21 years of age All Phase N/A
D Daniel Bowers, MD

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.

- 59 years of age All Phase 2
S Sara Loveless, BSN, RN

Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant

Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy, and lung injury affects as many as 25% of children receiving HSCT. Improved transplant techniques and major improvements in survival mean that HSCT is being more widely used, and more mismatched grafts are being used. Bronchiolitis obliterans (BO) is …

5 - 60 years of age All Phase 2

Simplify language using AI